首页> 外文期刊>Bioorganic and medicinal chemistry >Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity
【24h】

Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity

机译:3-(1,3-二苯基-1H-吡唑-4-基)-N-苯基丙烯酰胺衍生物作为HDAC活性抑制剂的合成,生物学评估和分子对接研究

获取原文
获取原文并翻译 | 示例
           

摘要

In present study, a series of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N- phenylacrylamide derivatives (5a-8d) were designed, synthesized, and evaluated for HDAC inhibition and tumor cell antiproliferation. All of these compounds are reported for the first time, the chemical structures of these compounds were confirmed by means of 1H NMR, ESI-MS and elemental analyzes. Among the compounds, compound 8c showed the most potent biological activity against HCT116 cancer cell line (IC 50 of 0.42 ± 0.02 μM for HDAC-1 and IC 50 = 0.62 ± 0.02 for HCT116). Docking simulation was performed to position compound 8c into the HDAC active site to determine the probable binding model. The results of antiproliferative assay and western-blot demonstrated that compound 8c with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent against HCT116 cancer cell.
机译:在本研究中,设计,合成了一系列3-(1,3-二苯基-1H-吡唑-4-基)-N-苯基丙烯酰胺衍生物(5a-8d),并评估了其对HDAC的抑制作用和对肿瘤细胞的抗增殖作用。所有这些化合物都是首次报道,这些化合物的化学结构通过1 H NMR,ESI-MS和元素分析得到了证实。在这些化合物中,化合物8c对HCT116癌细胞系表现出最强的生物学活性(HDAC-1的IC 50为0.42±0.02μM,HCT116的IC 50 = 0.62±0.02)。进行对接模拟以将化合物8c置于HDAC活性位点,以确定可能的结合模型。抗增殖试验和蛋白质印迹的结果表明,在肿瘤生长抑制中具有有效抑制活性的化合物8c可能是针对HCT116癌细胞的潜在抗癌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号